Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Wei

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
Japanese Journal of Clinical Oncology|July 29, 2021
Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapyTakahiro Yamauchi, Chikashi Yoshida, Kensuke Usuki, et al.
British Journal of Haematology|June 5, 2026
BCL-2 and MCL1 co-inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A-rearranged acute lymphoblastic leukaemiaMawar Karsa, Ayu Karsa, Dayna Spurling, et al.
Molecular Cell|July 2, 2026
Cytosolic EZH2-IMPDH2 complexes regulate melanoma progression and metastasis via GTPGamze Kuser-Abali, Fumihito Noguchi, Peinan Zhao, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2019
BCL-2 family protein BOK is a positive regulator of uridine metabolism in mammalsRahul Srivastava, Zhipeng Cao, Christina Nedeva, et al.
Cell Stem Cell|December 26, 2017
Inhibition of Endosteal Vascular Niche Remodeling Rescues Hematopoietic Stem Cell Loss in AMLDelfim Duarte, Edwin D Hawkins, Olufolake Akinduro, et al.
Science Translational Medicine|May 20, 2016
The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemiaGabriela Brumatti, Chunyan Ma, Najoua Lalaoui, et al.
Blood Advances|September 8, 2022
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentationHarry J Iland, Nigel Russell, Richard Dillon, et al.
Journal of Medicinal Chemistry|June 18, 2013
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XLBrad E Sleebs, Wilhemus J A Kersten, Sanji Kulasegaram, et al.
The New England Journal of Medicine|March 2, 2017
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic LeukemiaHagop Kantarjian, Anthony Stein, Nicola Gökbuget, et al.
Blood Advances|June 23, 2020
Cotargeting BCL-2 and MCL-1 in high-risk B-ALLDonia M Moujalled, Diane T Hanna, Soroor Hediyeh-Zadeh, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Japanese Journal of Clinical Oncology|July 29, 2021
Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapyTakahiro Yamauchi, Chikashi Yoshida, Kensuke Usuki, et al.
British Journal of Haematology|June 5, 2026
BCL-2 and MCL1 co-inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A-rearranged acute lymphoblastic leukaemiaMawar Karsa, Ayu Karsa, Dayna Spurling, et al.
Molecular Cell|July 2, 2026
Cytosolic EZH2-IMPDH2 complexes regulate melanoma progression and metastasis via GTPGamze Kuser-Abali, Fumihito Noguchi, Peinan Zhao, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2019
BCL-2 family protein BOK is a positive regulator of uridine metabolism in mammalsRahul Srivastava, Zhipeng Cao, Christina Nedeva, et al.
Cell Stem Cell|December 26, 2017
Inhibition of Endosteal Vascular Niche Remodeling Rescues Hematopoietic Stem Cell Loss in AMLDelfim Duarte, Edwin D Hawkins, Olufolake Akinduro, et al.
Science Translational Medicine|May 20, 2016
The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemiaGabriela Brumatti, Chunyan Ma, Najoua Lalaoui, et al.
Blood Advances|September 8, 2022
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentationHarry J Iland, Nigel Russell, Richard Dillon, et al.
Journal of Medicinal Chemistry|June 18, 2013
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XLBrad E Sleebs, Wilhemus J A Kersten, Sanji Kulasegaram, et al.
The New England Journal of Medicine|March 2, 2017
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic LeukemiaHagop Kantarjian, Anthony Stein, Nicola Gökbuget, et al.
Blood Advances|June 23, 2020
Cotargeting BCL-2 and MCL-1 in high-risk B-ALLDonia M Moujalled, Diane T Hanna, Soroor Hediyeh-Zadeh, et al.
Pageof 10